It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire all outstanding shares of 2seventy bio for $5, valuing the deal at ~$286m. 2seventy bio, a Cambridge-based biotech ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

On March 10, 2seventy bio announced a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS). Under the terms of the agreement, BMS will commence a tender offer to acquire all ...

Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... BMY announced that it was acquiring 2seventy bio for $286 million. The transaction involved the ...

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and ... Write to [email protected] Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities ...